News >

O'Neil Shares Insight on Growing Therapeutic Arsenal for GI Tract NETs

Caroline Seymour
Published: Monday, Jun 25, 2018

Bert O’Neil, MD

Bert O’Neil, MD
Physicians have another means of treatment following the FDA approval of Lutathera (lutetium Lu 177 dotate) in January 2018 for patients with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

The approval garnered great excitement; however, Bert H. O’Neil, MD, said that though the treatment is going to be a “game changer” for patients with receptor-positive disease, Lutathera should be reserved for those who progress on a somatostatin analog.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x